New study highlights impact of socioeconomic factors on ADHD in autistic youth

The associations between neighborhood characteristics and symptoms of attention-deficit/hyperactivity disorder (ADHD) among children.

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy

Share this article Cerevance’s CVN424 is a non-dopamine G protein-coupled receptor 6 (GPR6) inhibitor. Image Credit: Pla2na / Shutterstrock. US-based Cerevance has secured $47m in

April 26, 2024

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize

September 5, 2024

De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Rapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with conventional proteomics to uncover functional and neutralizing

October 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.